{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:17Z","timestamp":1786119617459,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,1]]},"DOI":"10.1097\/qai.0b013e31820a8226","type":"journal-article","created":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T03:03:23Z","timestamp":1297393403000},"page":"S68-S75","source":"Crossref","is-referenced-by-count":63,"title":["Integration of Buprenorphine\/Naloxone Treatment into HIV Clinical Care: Lessons From the BHIVES Collaborative"],"prefix":"10.1097","volume":"56","author":[{"given":"Linda","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Netherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P","family":"Flanigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Fiellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L","family":"Altice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210131","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1089\/apc.2008.0005","article-title":"Health-related quality of life in HIV-infected patients: the role of substance use.","volume":"22","author":"Korthuis","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"R2-11-20210131","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1080\/09540120701351888","article-title":"The impact of illicit drug use and substance abuse treatment on adherence to HAART.","volume":"19","author":"Hicks","year":"2007","journal-title":"AIDS Care"},{"key":"R3-11-20210131","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/aid.2006.22.715","article-title":"Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.","volume":"22","author":"Rodriguez-Arenas","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R4-11-20210131","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(10)60829-X","article-title":"Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.","volume":"376","author":"Altice","year":"2010","journal-title":"Lancet"},{"key":"R5-11-20210131","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.02.003","article-title":"Antiretroviral adherence and HIV treatment outcomes among HIV\/HCV co-infected injection drug users: the role of methadone maintenance therapy.","volume":"84","author":"Palepu","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"R6-11-20210131","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2005.06.014","article-title":"Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs.","volume":"108","author":"Saxon","year":"2005","journal-title":"Pharmacol Ther"},{"key":"R7-11-20210131","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.","volume":"343","author":"Johnson","year":"2000","journal-title":"N Engl J Med"},{"key":"R8-11-20210131","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: how to use it right.","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R9-11-20210131","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jsat.2006.11.009","article-title":"Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients.","volume":"33","author":"Maremmani","year":"2007","journal-title":"J Subst Abuse Treat"},{"key":"R10-11-20210131","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","article-title":"From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.","volume":"70","author":"Jaffe","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R11-11-20210131","first-page":"731","article-title":"In-office opiate treatment not a panacea: physicians slow to embrace therapeutic option.","volume":"290","author":"Vastag","year":"2009","journal-title":"JAMA"},{"key":"R12-11-20210131","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/archinte.165.15.1769","article-title":"Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.","volume":"165","author":"Turner","year":"2005","journal-title":"Arch Intern Med"},{"key":"R13-11-20210131","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.drugpo.2007.03.001","article-title":"Integration and co-location of HIV\/AIDS, tuberculosis and drug treatment services.","volume":"18","author":"Sylla","year":"2007","journal-title":"Int J Drug Policy"},{"key":"R14-11-20210131","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archinte.161.1.85","article-title":"Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives.","volume":"161","author":"Samet","year":"2001","journal-title":"Arch Intern Med"},{"key":"R17-11-20210131","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5694\/j.1326-5377.2003.tb05417.x","article-title":"A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial.","volume":"179","author":"Gibson","year":"2003","journal-title":"Med J Aust"},{"key":"R18-11-20210131","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00001888-200105000-00007","article-title":"Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders.","volume":"76","author":"Miller","year":"2001","journal-title":"Acad Med"},{"key":"R19-11-20210131","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5993\/AJHB.30.5.11","article-title":"Clinic-based treatment for opioid dependence: a qualitative inquiry.","volume":"30","author":"McMurphy","year":"2006","journal-title":"Am J Health Behav"},{"key":"R20-11-20210131","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s11606-010-1377-y","article-title":"The physician clinical support system-buprenorphine (PCSS-B): a novel project to expand\/improve buprenorphine treatment.","volume":"25","author":"Egan","year":"2010","journal-title":"J Gen Intern Med"},{"key":"R21-11-20210131","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11606-008-0881-9","article-title":"Integrating buprenorphine treatment into office-based practice: a qualitative study.","volume":"24","author":"Barry","year":"2009","journal-title":"J Gen Intern Med"},{"key":"R22-11-20210131","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1086\/500200","article-title":"Models for integrating buprenorphine therapy into the primary HIV care setting.","volume":"42","author":"Basu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R23-11-20210131","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment.","volume":"36","author":"Netherland","year":"2009","journal-title":"J Subst Abuse Treat"},{"key":"R24-11-20210131","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMcp013579","article-title":"Clinical practice. Office-based treatment of opioid-dependent patients.","volume":"347","author":"Fiellin","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"R25-11-20210131","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1080\/10550490490440843","article-title":"Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care.","volume":"13","author":"Fiellin","year":"2004","journal-title":"Am J Addict"},{"issue":"Suppl 1","key":"R26-11-20210131","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/QAI.0b013e3182097426","article-title":"Botsko M, et al, and BHIVES Collaborative. The BHIVES Collaborative: overview and organization of a multi-site demonstration of integrated buprenorphine and HIV treatment.","volume":"56","author":"Weiss","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R27-11-20210131","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/QAI.0b013e318209740f","article-title":"A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care.","volume":"56","author":"Cheever","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R28-11-20210131","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jama.2007.26","article-title":"The meaning of translational research and why it matters.","volume":"299","author":"Woolf","year":"2008","journal-title":"JAMA"},{"key":"R29-11-20210131","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.publhealth.031308.100049","article-title":"Diffusion theory, and knowledge dissemination, utilization, and integration in public health.","volume":"30","author":"Green","year":"2009","journal-title":"Annu Rev Public Health"},{"key":"R31-11-20210131","first-page":"1101","article-title":"Qualitative methods: what are they and why use them?","volume":"34","author":"Sofaer","year":"1999","journal-title":"Health Serv Res"},{"key":"R32-11-20210131","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/intqhc\/14.4.329","article-title":"Qualitative research methods.","volume":"14","author":"Sofaer","year":"2002","journal-title":"Int J Qual Health Care"},{"issue":"Suppl 1","key":"R33-11-20210131","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1097\/QAI.0b013e3182097561","article-title":"Gass J, et al, and BHIVES Collaborative. Patient perspectives on buprenorphine\/naloxone treatment in the context of HIV care.","volume":"56","author":"Egan","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R34-11-20210131","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/QAI.0b013e318209d3b9","article-title":"Weiss L, et al, and BHIVES Collaborative. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine\/naloxone (bup\/nlx) and HIV care.","volume":"56","author":"Chaudhry","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R35-11-20210131","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1097\/QAI.0b013e3182097576","article-title":"Cunningham C, et al, and BHIVES Collaborative. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine\/naloxone.","volume":"56","author":"Sullivan","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R36-11-20210131","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1097\/QAI.0b013e31820a9a82","article-title":"Botsko M, et al, and BHIVES Collaborative. Opioid prescribing and provider confidence recognizing opioid abuse in HIV primary care settings.","volume":"56","author":"Lum","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R37-11-20210131","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1097\/QAI.0b013e31820a9a97","article-title":"Policy implications of integrating buprenorphine\/naloxone treatment and HIV care.","volume":"56","author":"Finkelstein","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R38-11-20210131","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/QAI.0b013e3182097537","article-title":"Drug treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone.","volume":"56","author":"Fiellin","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R39-11-20210131","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/QAI.0b013e31820a9a66","article-title":"Botsko M, et al, and BHIVES Collaborative. The cost of integrated HIV care and buprenorphine\/naloxone treatment: results of a cross-site evaluation.","volume":"56","author":"Schackman","year":"2011","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAI.0b013e31820a8226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:05Z","timestamp":1786041905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201103011-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":36,"journal-issue":{"issue":"Supplement 1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31820a8226","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,1]]}}}